Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc.

81.96
EUR
-2.26
(-2.68%)
-13.28EPS
4.93BMarket Cap
Mar 10Next Earn
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
0.63
2.28
4.56
7.09
10.39
11.2
Basic EPS, GAAP
- -
-4.58
-4.09
-2.77
-4.01
-4
-1.85
-0.47
-15.09
Free Cash Flow per Basic Share
- -
-3.45
-3.54
-5.01
-3.56
-2.23
-0.22
1.09
-5.16
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.45
5.77
5.78
3.93
3.84
5.32
4.67
6.06
-0.83
Tangible Book Value per Share
-0.45
5.77
5.78
3.32
2.25
-0.09
-0.5
1.04
-5.06
Basic Weighted Avg Shares
23
11
25
30
34
41
48
50
60
Sales/Revenue/Turnover
- -
- -
- -
19
77
186
337
521
671
Operating Margin (%)
- -
- -
- -
-906.12
-170.28
-58.57
-26
-4.25
-20.88
Depreciation Expense
- -
- -
1
1
3
11
24
24
27
Net Income, GAAP
- -
-53
-103
-84
-136
-163
-88
-23
-904
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
-438.85
-176.05
-87.68
-26.1
-4.48
-134.75
Working Capital
50
106
218
124
125
300
266
344
304
LT Debt
- -
3
3
2
1
307
316
317
741
Total Equity
-10
130
172
120
142
249
226
315
-54
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
-68.29
-57.47
-103.46
-83.65
-37.08
-8.65
- -

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
2
2
3
LT Borrowings
310
750
731
LT Finance Leases
11
10
10
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
61
65
65
Market Capitalization
5,634
7,738
5,585

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
569
636
587
Cash, Cash Equivalents & STI
386
438
374
Accounts Receivable, Net
133
145
156
Inventories
26
26
25
Total Current Liabilities
273
223
283
Payables & Accruals
209
167
215
ST Debt
2
2
3
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
18.66%
39.47%
Free Cash Flow
- -
-135.55%
-614.37%
Net Income, GAAP
- -
-11.26%
-73.43%
Sales/Revenue/Turnover
- -
- -
54.74%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
69
78
90
99
337
2025
112
128
133
149
521
2026
160
176
186
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.54
-0.52
-0.3
-0.49
-1.85
2025
-0.3
-0.12
0.06
-0.11
-0.47
2026
-13.43
-1.06
-0.62
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Christopher Peetz
Full Time Employees
372
Sector
Health technology
Industry
Pharmaceuticals: major
Address
989 East Hillsdale Boulevard Foster City CA United States 94404
IPO Date
Jul 18, 2019
Business
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative treatments for severe rare and orphan diseases, particularly those affecting the liver. The company’s flagship product, LIVMARLI (maralixibat), an ileal bile acid transporter (IBAT) inhibitor, is approved in the United States and Europe for treating cholestatic pruritus in patients with Alagille syndrome (ALGS) aged three months and older (two months and older in Europe). LIVMARLI also holds U.S. approval for cholestatic pruritus in progressive familial intrahepatic cholestasis (PFIC) patients 12 months and older, and European approval for PFIC patients three months and older. Beyond LIVMARLI, Mirum is advancing Volixibat, another IBAT inhibitor, through late-stage clinical studies for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), having reported positive interim results for PBC showing significant improvements in pruritus and fatigue. The company's pipeline further includes CHOLBAM (cholic acid) capsules for bile acid synthesis disorders and CHENODAL (chenodiol) tablets for cerebrotendinous xanthomatosis (CTX), both FDA-approved. Mirum also has MRM-3379, a PDE4D inhibitor, in Phase 2 development for Fragile X syndrome. Mirum Pharmaceuticals, established in 2018 and headquartered in Foster City, California, generates revenue primarily from product sales across key markets including the United States and Europe. The company reported strong financial performance in 2024 and Q3 2025, with increasing product sales and a move to net profitability, leading to raised revenue guidance for 2025.

Company News

  • AMG TimesSquare Small Cap Growth Fund Q3 2026 Portfolio Activity

  • Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • MIRM's Brelovitug Scores Second Phase III Win, Nears BLA Filing in HDV

  • Mirum's liver infection drug lowers virus levels in second late-stage study

  • Mirum Pharmaceuticals Announces Primary Endpoint Met in AZURE-4 Phase 3 Study and Highlights Long-Term Brelovitug Data Presented at AASLD

  • Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) CEO Sells $1,800,000.00 in Stock

  • Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) CEO Sells $1,800,000.00 in Stock

  • GeneDx and Mirum Pharmaceuticals Launch Sponsored Testing Programs to Help Patients Find Answers Through Comprehensive Genetic Testing

  • Mirum Pharmaceuticals, Inc. (MIRM) Q3 2026 Earnings Call Transcript

  • Mirum Pharmaceuticals Q3 Earnings Call Highlights

  • Here's What Key Metrics Tell Us About Mirum Pharmaceuticals (MIRM) Q3 Earnings

  • Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Tops Revenue Estimates

  • Mirum Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update

  • Mirum Pharmaceuticals Showcases Momentum Across Rare Liver Disease Portfolio with New Data at AASLD's The Liver Meeting® 2026

  • Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

  • Mirum Pharmaceuticals Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to

  • Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock Rated “Moderate Buy” by Wall Street Brokerages

  • Head-To-Head Survey: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) versus Mirum Pharmaceuticals (NASDAQ:MIRM)

  • Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Mirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver Diseases